US FDA approves Eyenovia`s eye drug, Formosa Pharma says
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália
Formosa Pharmaceuticals has handed over another set of regional rights to its near-approval eye drug candidate APP13007, striking a deal that positions Cristália Produtos Químicos Farmacêuticos to bring the product to market in Brazil.
Taiwan-based Formosa Pharmaceutical has entered into a licensing agreement with Eyenovia, whereby Eyenovia obtains exclusive US rights for the commercialisation of APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for the treatment of inflammation and pain following ocular surgery.
Formosa Pharmaceuticals along with AimMax Therapeutics has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for APP13007, a new formulation to treat inflammation and pain after ocular surgery.
TAIPEI, May 4, 2023 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surgery. This proprietary homogeneous nanosuspension has a solution-like appearance which offers great comfort to the eyes and enhanced drug penetration into ocular tissues.
Ophthalmic technology firm Eyenovia and Formosa Pharmaceuticals have entered a collaboration agreement to develop new ophthalmic therapeutics.
Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics have reported successful top-line results from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a potent corticosteroid, clobetasol propionate(0.05%), for the treatment of inflammation and pain after cataract surgery.